
BI initiates Phase II testing of COVID-19 drug
A new potential weapon against severe complications such as ARDS caused by the new coronavirus SARS-CoV-2 have been advanced by Boehringer Ingelheim...

Avantium NV bags money for demo plant
The new grant is part of a €30m financing mix that Avantium and the Groningen consortium announced this January. FDCA is the key building block for...

Polyphor AG bags funding for murepavadin
Swiss Polyphor AG (Allschwil) is developing its lead Outer Membrane Protein Targeting Antibiotic (OMPTA) candidate inhaled murepavadin against...

Roche licences antiviral nucleoside from Atea
Under the agreement, Roche will pay US$350m in cash for ex US-distribution of Atea Pharmaceuticals antiviral Phase II candidate. Atea has the option...

Centogene and Anylam launch clinical programme
ATTRv is an autosomal dominant condition caused by a pathogenic variant in the TTR gene coding for transthyretin (prealbumin)....

Vifor Pharma in US$100m licence deal with Cara Therapeutics
Under the licence deal with the US company Cara Therapeutics Inc., Swiss Vifor Pharma has acquired the US commercialisation rights for intravenous...

Moderna to file for EU approval of mRNA-1273 vaccine
Modernas primary analysis of the COVE Phase III data was based on 196 cases, of which 185 cases of COVID-19 were observed in the placebo group versus...